Novartis (NVS) Zen Horizon Research Report

Kisqali (ribociclib, breast cancer CDK4/6 inhibitor) - 2024-2025 sales growth of 60%+

• Pluvicto (177Lu-PSMA-617, prostate cancer radioligand therapy, RLT) - global leader in RLT, with annual sales of about $1.5-1.8 billion

• Tabrecta (capmatinib, METex14-positive NSCLC)

• Scemblix (asciminib, third-generation BCR-ABL inhibitor for chronic myeloid leukemia)

• Immunology - about 15% of revenue

Cosentyx (secukinumab, IL-17A antibody for psoriasis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, and other indications) - annual sales of about $6.0-6.5 billion

• Neuroscience - about 10% of revenue

Kesimpta (ofatumumab, subcutaneous CD20 antibody for multiple sclerosis) - annual sales of about $3.0 billion

• Mayzent (siponimod, progressive MS)

• Rare Diseases / Hematology - about 10% of revenue

Lutathera (177Lu-DOTATATE, neuroendocrine tumor RLT)

• Promacta/Revolade (eltrombopag, thrombocytopenia)

• Adakveo (crizanlizumab, sickle cell disease)

• Other + legacy drugs - about 10% of revenue

Key financial profile (2025 fiscal year TTM):

• Revenue $56.6B

• EBITDA $22.9B, EBITDA margin 40.5%

• Operating margin 30.48%

• Net margin 23.92%

• ROE 34.93%

• EPS (TTM) $6.98

• Dividend yield 3.18% (28 consecutive years of dividend increases)

• Free cash flow about $15B

Current market positioning (close on 2026-06-05):

• Share price $149.16

• Market cap $284.6B

• TTM PE 21.37x

• Forward PE 16.89x (market expects EPS growth in 2026/2027, even with pressure from the Entresto patent cliff)

• EV/EBITDA 14.49x

• P/S 5.03x

Key positioning: Novartis is one of the few large innovative pharma companies with moderate valuation multiples, a 30%+ operating margin, 28 consecutive years of dividend increases, and a deep R&D pipeline. It is a typical "defensive + moderate growth" shareholder return story.

2. Vertical View (1): From the Ciba-Geigy / Sandoz Merger to the Pure-Play Transformation (1996-2024)

2.1 Merger Origins (1996)

• March 1996: Switzerland's two major chemical / pharmaceutical companies, Ciba-Geigy and Sandoz Laboratories, merged to form Novartis AG.

• At the time of the merger, the company had a market value of about CHF 75 billion and was the largest company on the Swiss stock exchange.

• In its early years, the merged company retained three major business lines: prescription drugs / generics (Sandoz) / crop protection and seeds (Syngenta).

2.2 Divestitures and Focus (2000-2018)

• 2000: Divested the agribusiness unit, leading to the independent listing of Syngenta.

• 2014: Novartis and GlaxoSmithKline (GSK) completed a "three-way asset swap": Novartis sold its vaccines business, excluding influenza, to GSK, acquired GSK's oncology business, and formed a consumer healthcare joint venture.

• February 2018: Vas Narasimhan (an Indian-American physician and former Harvard Medical School executive) became CEO, replacing Joe Jimenez.

• July 2018: Spun off Alcon (ophthalmic devices and contact lenses) as an independent listed company, ALC.SW / ALC.NYSE.

2.3 Transformation into a Pure-Play Innovative Medicines Company (2020-2024)

After Narasimhan took office, the strategic direction became clear: divest non-core businesses and focus on originator innovative medicines.

• 2019: Sold the consumer healthcare joint venture stake to GSK.

• 2022-2023: Evaluated strategic options for Sandoz: sale vs spinoff. Novartis ultimately chose a spinoff to preserve greater strategic flexibility.

• October 2023: Sandoz spinoff completed. Novartis shareholders received 1 share of Sandoz Group AG (SDZ.SW) for every 1 Novartis share held.

• 2024: Novartis began reporting results as a "100% innovative medicines" company, and its valuation multiple moved meaningfully higher, with forward PE rising from about 13x to 17x.

2.4 Major M&A and Licensing (2020-2025)

• 2020: Acquired The Medicines Company for $9.7B, gaining inclisiran, now Leqvio, an RNAi cholesterol-lowering drug.

• January 2024: Acquired U.S. rights to Cytokinetics' aficamten (an investigational cardiomyopathy drug) for $2.9B.

• August 2024: Acquired MorphoSys AG for $1.7B, gaining pelabresib, an investigational myelofibrosis drug, plus tulmimetostat.

• May 2025: Novartis completed the acquisition of Anthos Therapeutics, gaining abelacimab, an anticoagulant; Anthos had previously been owned by Blackstone Life Sciences.

3. Vertical View (2): Financial Performance and Blockbuster Drug Life Cycles

3.1 Revenue and Profit Trends (2018-2025)

Key observations:

• Revenue basis changed after the Sandoz spinoff (2023-10): 2023 reported revenue excluded Sandoz, so revenue "fell" from 50.5 in 2022 to 45.4 in 2023. This was an accounting basis change, not a real operating decline.

• Operating margin continued to rise in 2024-2025 (26.6% -> 29.0% -> 30.6%): after the Sandoz spinoff, the remaining innovative medicines business had a higher gross margin, supported by cost-out and growth from Entresto/Pluvicto/Kisqali/Cosentyx.

• 2025 Q1 revenue fell 0.7% YoY: the root cause was U.S. generic competition for Entresto beginning to erode about $300-500 million per quarter. This is the largest risk signal for 2026-2028.

3.2 Blockbuster Drug Life Cycles (2024 -> 2030)

Key warning signal: Entresto is Novartis' largest product, accounting for 13-15% of revenue. U.S. generic competition starts from 2025-Q4, and sales are expected to fall from $7.5 billion to the $2.0-3.0 billion range during 2026-2028. This is Novartis' largest near-term "patent cliff."

3.3 Balance Sheet and Cash Flow

• Estimated at 2025 year-end: net debt of $25-30B (including financing for the MorphoSys/Anthos acquisitions)

• Net Debt / EBITDA: ~1.2-1.5x (healthy and relatively low)

• Free cash flow TTM: ~$15B

• FCF conversion: ~75-85%

• 2025 share repurchase: $10B authorization program in progress

3.4 Capital Return Record

• Dividend: increased for 28 consecutive years, since 1997, making Novartis one of the few innovative pharma companies with a long record of rising dividends

• Dividend yield: 3.18% (above peer LLY at 1.0%, below PFE at 6.5%)

• Buybacks: repurchased $5-10B per year in 2024-2025

4. Moat Analysis

4.1 Patent Protection and Regulatory Barriers (Strong)

• A single new drug requires 10+ years and $2.0-3.0 billion of R&D spending from clinical development to launch, while FDA / EMA approval rates are only about 10%.

• Once launched, a blockbuster drug can enjoy 10-15 years of effective patent protection in practice, since 5-7 years often pass from patent filing to first commercial sale.

• Novartis currently has about 25 Phase III candidates / about 70 Phase II candidates, placing its pipeline depth in the industry top 5.

4.2 Innovative Drug R&D Capability (Strong)

• 2024 R&D spending was $11.4B (about 20% of revenue), ranking among the top 5 global pharma companies.

• NIBR (Novartis Institutes for BioMedical Research): U.S. headquarters in Cambridge, plus 9 research centers globally and about 6,000 researchers.

• Received 25 FDA new drug approvals during 2020-2025, ranking in the industry top 3 by volume.

4.3 Therapeutic Focus and Depth (Moderately Strong)

• The company has leading products plus investigational pipelines across four major areas: cardiovascular / oncology / immunology / neuroscience.

• Compared with Eli Lilly's depth in GLP-1, AbbVie's dominance in immunology, or Merck's KEYTRUDA franchise, Novartis has weaker "absolute leadership" in any single therapeutic area.

4.4 Radioligand Therapy (RLT) Platform Moat (Strong)

• Pluvicto (prostate cancer RLT): the first FDA-approved RLT for metastatic prostate cancer globally, with sales growing exponentially since its 2022 launch.

• Lutathera (neuroendocrine tumors): first-line RLT for neuroendocrine tumors.

• Through the 2018 acquisition of Advanced Accelerator Applications ($3.9B) and the 2020 acquisition of Endocyte ($2.1B), Novartis built the world's most complete RLT manufacturing network, including ¹⁷⁷Lu isotope production, automated synthesis, cold-chain logistics, and clinical training. This is a real moat. Competitors such as Bayer, Pfizer, and Eli Lilly would need 3-5 years to catch up.

4.5 Overall Assessment

Overall moat score 4/5 (Strong). Novartis benefits from four layers of moat: patents + R&D + therapeutic depth + the RLT platform. The largest vulnerability is that a single blockbuster, Entresto, accounts for 13-15% of revenue and is about to face a patent cliff, creating a significant short-term earnings impact.

5. Horizontal View: Competitive Landscape

5.1 Direct Comparables

5.2 Valuation Positioning

• NVS forward PE 16.9x: near the median for large innovative pharma companies, much cheaper than LLY (35x) and somewhat more expensive than "value trap" candidates such as PFE/GSK/BMY.

• Dividend yield 3.18%: above LLY/MRK/ABBV, making Novartis a choice for income-oriented investors.

• EV/EBITDA 14.5x: around the industry average, reflecting a balance of quality and growth.

5.3 Key Competitive Nodes

• GLP-1 weight-loss drugs vs Novartis: Novartis has no GLP-1 blockbuster. This is the largest disruption in the pharma industry during 2024-2026, led by the LLY/NVO duopoly. Whether Novartis enters the GLP-1 pipeline, such as through oral GLP-1 or second-generation RNAi, is a key point to watch.

• PCSK9 RNAi (Leqvio) vs antibodies (Repatha / Praluent): Leqvio requires only 2 injections per year, while Repatha is injected every two weeks. Leqvio has a convenience advantage, but market penetration has been slower than expected.

• Breast cancer CDK4/6 (Kisqali) vs Ibrance (Pfizer): Kisqali rapidly gained share from Ibrance during 2024-2026, supported by stronger PFS/OS data.

6. Valuation Analysis (Three Scenarios)

6.1 Horizontal Valuation Comparison

Among 6 of the world's top 10 innovative pharmaceutical companies, Novartis sits near the median forward PE:

• Expensive end: LLY (35x), Roche (17x)

• Mid-range: NVS (16.9x), AbbVie (14x), Merck (11x)

• Cheap end: Pfizer (9x), GSK (9x), BMY (8x)

6.2 Three Valuation Scenarios

Conservative / Bear $100-115 (potential downside ~23-33%)

• Triggers: Entresto generic competition proceeds faster than expected, with 2026-2027 sales down 70%+; clinical failures in the new-drug pipeline; valuation multiple compresses to forward PE 13-15x

• Valuation assumptions: sustainable EPS $7.5-8, forward PE 13-15x

Reasonable / Base $125-155 (range midpoint $140, about -6% from the current price)

• Triggers: Entresto generic competition unfolds at the expected pace; growth from Pluvicto/Kisqali/Kesimpta offsets Entresto decline; overall revenue growth remains at 3-5%

• Valuation assumptions: sustainable EPS $8-9, forward PE 15-17x

• Sell-side consensus target price of about $150 sits near the midpoint of this range

Optimistic / Bull $170-195 (potential upside ~14-31%)

• Triggers: Entresto replacements, such as aficamten / pelabresib, are approved and ramp quickly; Pluvicto expands into earlier-line prostate cancer indications; revenue growth accelerates to 7-10%

• Valuation assumptions: sustainable EPS $9-11, forward PE 17-19x

6.3 Setting a Reasonable Buy Price

The reasonable buy price ceiling is $130 (slightly above the lower end of the base range). This means that when the share price falls below $130, the odds begin to favor buyers as downside risk to the bear range of $100-115 becomes more balanced against upside to the base midpoint of $140 or the bull case of $170+. The current price of $149.16 is in the upper one-third of the base range. Neutral expectations are already fully priced in, and the margin of safety is not meaningful.

7. Bull-Bear Debate

7.1 Core Bull Arguments

• A typical defensive quality asset: high dividend yield (3.18%) + 28 consecutive years of dividend growth + 30% operating margin + 35% ROE = a textbook "stable income + quality growth" profile.

• Valuation re-rating potential after the Sandoz spinoff: the move from forward PE 13x to 17x has been partly realized, but there may still be 1-2 turns of room versus LLY/RHHBY.

• RLT platform leader: continued Pluvicto growth + stable Lutathera + the world's only complete global RLT manufacturing network.

• Strong pipeline depth: 25+ Phase III candidates + about 70 Phase II candidates + 25 FDA approvals during 2020-2025.

• Stable cash flow conversion: about $15B of annual free cash flow, continued buyback authorization, and a healthy net debt position.

7.2 Core Bear Arguments

• Entresto patent cliff: U.S. generic competition begins from 2025-Q4, with 2026-2028 annual revenue losses of $4.0-5.0 billion from the company's largest product.

• No GLP-1 exposure: Novartis has missed one of the largest pharma trends of 2024-2030; the weight-loss drug market is expected to exceed $150 billion by 2030.

• Cosentyx patent expiry approaches in 2030: another potential risk at about $6.0 billion per year.

• Large M&A integration execution: MorphoSys (2024) and Anthos (2025) require a 2-3 year observation period.

• Valuation already partly reflects the pure-play transition: after forward PE rose from 13x to 17x, further multiple expansion is limited.

• Large-cap growth ceiling: with a $56.6 billion revenue base, annual revenue growth of 3-5% is likely the upper bound.

7.3 Integrated Bull-Bear Assessment

The bull case rests on confirmed cash flow quality and a track record of shareholder returns. The bear case centers on the patent cliff and strategic gaps over the next 2-4 years. The current price of $149.16 broadly reflects neutral expectations. It is neither overly optimistic, as in pricing a smooth Entresto transition, nor overly pessimistic, as in pricing permanent -5% growth. This is the core reason for a "Hold" rather than a "Buy."

8. Pre-Mortem Risk List

Assume that 12-24 months from now, the share price has fallen from the current $149.16 to $110. Possible post-mortem explanations would be:

Major Macro Risks

• 2026-2028 U.S. drug price negotiations (IRA): Novartis' Entresto, Promacta, and Cosentyx could all enter CMS negotiation lists, directly compressing margins.

• European drug pricing reform: from 2026, the EU is expected to strengthen drug reference pricing, putting marginal pressure on profitability for European revenue, which accounts for about 40%.

• Emerging-market expansion opportunities: growth in middle-class chronic disease populations in China / India / Brazil is a long-term opportunity.

9. Zen Horizon Synthesis: Investment Judgment

9.1 Rating Band Positioning

Using a six-level rating framework:

• Business quality: ✓ Strong - 30% operating margin, 35% ROE, and 28 consecutive years of dividend growth

• Industry cycle: ✓ Moderate - pharma is broadly stable, but Entresto faces patent-cliff pressure

• Management: ✓ Good - Narasimhan has led a successful transformation over 6 years

• Moat: ✓ Strong - four-layer moat from patents + R&D + RLT platform

• Valuation margin of safety: ~ Moderate - forward PE 16.9x already reflects neutral expectations

• Downside risk: ~ Moderate - Entresto cliff is certain, and the new-drug pipeline remains uncertain

Overall judgment: "Hold" rating. Do not chase the stock, and do not rush to sell. Wait for valuation to converge or for clearer progress in the new-drug pipeline.

9.2 Specific Action Suggestions

Existing holders:

• Hold the stock and collect the 3.18% dividend plus the benefit of 28 consecutive years of dividend growth

• Set a stop-loss: a break below $130, the lower end of the base range, triggers trimming

• Add-on timing: share price falls below $125, while Pluvicto / Kisqali growth has not weakened

New buyers:

• Not recommended to initiate a position at the current $149 price

• Set a target buy price of ≤ $130 (roughly the reasonable buy price ceiling)

• If Entresto generic speed plus continued GLP-1 erosion triggers a valuation reset, NVS could fall into the $100-115 range. That would be the real margin-of-safety buying opportunity

Long-term holders (5+ years):

• If one believes RLT is one of the future mainstream directions in oncology treatment, Novartis is one of the purest global exposures

• Even if a position is initiated at the current price, 5-year return = 3% dividend x 5 + 5% EPS growth x 5 + stable valuation multiple = about 30-40% total return, including dividends

• Less upside elasticity than high-valuation peers such as LLY, but lower volatility

9.3 Key Monitoring Signals

Indicators to watch closely over the next 6-12 months:

• Quarterly Entresto sales curve: management's quarterly disclosure of Entresto U.S. vs international sales split. The pace of U.S. decline from 2026 Q1 is the core signal

• Quarterly Pluvicto growth: whether it can sustain 25-30% YoY growth

• Kisqali vs Ibrance market share: whether it continues taking share from Pfizer's Ibrance

• Aficamten Phase III interim results: whether the investigational cardiomyopathy drug can become the next-generation successor to Entresto

• Dividend growth guidance: whether management maintains a roughly 5% annual dividend growth path

• Buyback announcements: whether the company expands repurchase authorization with net debt/EBITDA at 1.2x

• CEO Narasimhan contract: whether there are signals of renewal before the 2028 contract expiry

10. Valuation Conclusion and Target Price Range

Current share price $149.16 (close on 2026-06-05)

• Conservative intrinsic value (Bear): $100-115 - triggered by a larger-than-expected Entresto sales decline + clinical failures in new drugs + valuation multiple compression

• Reasonable intrinsic value (Base): $125-155 - range midpoint $140, broadly consistent with sell-side consensus around $150

• Optimistic intrinsic value (Bull): $170-195 - triggered by rapid pipeline ramp-up + Pluvicto expansion + sustained valuation multiple

Reasonable buy price ceiling: $130 (slightly above the lower end of the base range) Trimming alert level: start trimming if the share price falls below $130 or forward PE drops below 14x Target sell price: $170+ (near the lower end of the bull range, with valuation already expanded close to its limit)

Rating: Hold

Reason summary: Novartis is a pure-play innovative medicines company after the Sandoz spinoff. Headquartered in Basel, Switzerland, it is one of the world's top ten pharmaceutical companies, with a 30% operating margin, 35% ROE, and 28 consecutive years of dividend growth. Business quality, moat depth, management execution, and capital return record are all excellent. But the current valuation already fully prices in neutral expectations: forward PE 16.9x, dividend yield 3.18%, and sell-side consensus target of about $150 imply only +1% upside.

The largest short-term risk is U.S. generic competition for Entresto, starting in 2025-Q4. Sales of this largest product, which accounts for 13-15% of revenue, will decline by $4.0-5.0 billion per year during 2026-2028, creating meaningful EPS pressure. Whether the bull drivers, including the RLT platform, Pluvicto growth, and Kisqali growth, can fully fill this gap is the most important issue to monitor over the next 24 months.

The core reason for "Hold" rather than "Buy" is that the margin of safety is not meaningful. A good business is not the same as a good entry point. Consider adding only after a pullback below $130 or after clear positive Phase III data for Entresto replacements such as aficamten / pelabresib.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.